1. Home
  2. ARTL vs PTIX Comparison

ARTL vs PTIX Comparison

Compare ARTL & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.42

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Logo Protagenic Therapeutics Inc.

PTIX

Protagenic Therapeutics Inc.

HOLD

Current Price

$0.74

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
PTIX
Founded
2011
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
3.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
ARTL
PTIX
Price
$1.42
$0.74
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
108.0K
149.6K
Earning Date
11-12-2025
11-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$0.70
52 Week High
$28.60
$14.28

Technical Indicators

Market Signals
Indicator
ARTL
PTIX
Relative Strength Index (RSI) 40.55 24.67
Support Level $1.48 $1.12
Resistance Level $1.82 $1.68
Average True Range (ATR) 0.16 0.17
MACD 0.04 -0.01
Stochastic Oscillator 39.55 3.50

Price Performance

Historical Comparison
ARTL
PTIX

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: